Navigation Links
Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
Date:2/12/2008

Recent Product Introductions Drive 49% Revenue Growth and Gross Margin of

66%

WESTFORD, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced record revenues and net income for the quarter and year ended December 31, 2007.

Fourth Quarter 2007 Financial Results

Revenues increased 49% to $36.6 million in the fourth quarter of 2007 from $24.6 million for the fourth quarter of 2006. Gross profit margin increased more than 600 basis points to 66% of total revenues compared with 60% for the same period in 2006. Fourth quarter 2007 net income was $5.3 million, or $0.41 per diluted share, compared with net income of $1.5 million, or $0.13 per diluted share, in the fourth quarter of 2006.

Non-GAAP net income, which excludes stock-based compensation expense and its related income tax effects, was $5.9 million, or $0.46 per diluted share, for the fourth quarter of 2007. This compares with non-GAAP net income of $2.5 million, or $0.21 per diluted share, in the fourth quarter of 2006, which excludes stock-based compensation expense and its related income tax effects. Please refer to the financial reconciliations included in this news release for a reconciliation of GAAP results to non-GAAP results for the three months ended December 31, 2007 and 2006.

"We concluded a banner year in 2007 with another quarter of record financial results, powered by continued customer demand for our flagship aesthetic laser systems," said President and Chief Executive Officer Michael Davin. "Laser product revenue increased 50% in the fourth quarter from the same period in
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
2. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
3. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
4. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
5. Immtech Reports Fiscal Third Quarter 2008 Results
6. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
7. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
8. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
9. Bunge Reports Fourth Quarter Net Income of $245 Million
10. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
11. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... researchers from the University of Leicester has furthered ... the potential to create new materials using nanosized ... published in the prestigious academic journal Physical ... to examine in rich detail the structure and ... an acetylene molecule and a single helium atom. ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... data from Phase 3 European clinical ... pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), ... prevalent serotypes associated with pneumococcal disease (PD), the leading cause ... , , The Phase 3 data presented at ...
... Syngenta today announced that it has ... antitoxin crop protection technology to the company,s portfolio. Circle ... reducing aflatoxin, a toxin that can develop in crops such ... , , "The acquisition of this technology adds ...
... ... Stage Solutions, Inc. has expanded its financial services offerings to further meet ... launched three new services: First, CFO on Demand - NSS partners with ... Strategic Finance - the Next Stage Solutions team equips its clients with ...
Cached Biology Technology:New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 2Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 3Next Stage Solutions Announces Three New Financial Services For Emerging Business 2Next Stage Solutions Announces Three New Financial Services For Emerging Business 3
(Date:7/25/2014)... for Medical Research have identified the functions of ... to triggering the mating process in mice. , They ... detect pheromones that indicate when a female is present. ... the female mouse is ovulating and ready to mate. ... Stowers, researchers believe mice developed this system through evolution ...
(Date:7/25/2014)... have detected an unknown interaction between microorganisms and salt. ... a droplet of salt water and is left to ... biomineralogical biosaline 3D morphologically complex formations, where they hibernate. ... The discovery was made by chance with a home ... Astrobiology journal and may help to find signs ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
... tissues and organs. Because these cells are able to grow ... they hold the key to groundbreaking new therapies. To help ... found a new way to culture cells in 3D a ... body grow and divide in a 3D environment, especially when ...
... of people suffer from Parkinson,s disease, a disorder of ... time. As the world,s population ages, it,s estimated that ... sharply. Yet despite several effective therapies that treat Parkinson,s ... it,s not known what exactly causes the disease, evidence ...
... now, it was presumed that the last glacial period ... return of milder weather began and melted away the ... now disproved by research headed by Professor Eske Willerslev ... Laura Parducci from the University of Uppsala, Sweden, and ...
Cached Biology News:Parkinson's disease stopped in animal model 2Parkinson's disease stopped in animal model 3Sturdy Scandinavian conifers survived Ice Age 2Sturdy Scandinavian conifers survived Ice Age 3
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Biology Products: